These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 401314)

  • 21. Adoptive immunity in mice challenged with L1210/DTIC clones.
    Canti G; Ricci L; Marelli O; Franco P; Nicolin A
    Cancer Immunol Immunother; 1987; 24(1):64-7. PubMed ID: 3545466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Contessa AR; Bonmassar A; Giampietri A; Circolo A; Goldin A; Fioretti MC
    Cancer Res; 1981 Jun; 41(6):2476-82. PubMed ID: 7016315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional studies of H-2k-like epitopes on DTIC treated and untreated L1210 (H-2d) clones.
    Marelli OE; Franco P; Labeta MO; Festenstein H
    J Immunogenet; 1989; 16(4-5):373-80. PubMed ID: 2639909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).
    Tentori L; Leonetti C; Lozupone F; Bonmassar E
    Cancer Immunol Immunother; 1995 Dec; 41(6):375-83. PubMed ID: 8635195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
    Testorelli C; Archetti YL; Aresca P; Del Vecchio L
    Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed-type hypersensitivity to sheep red blood cells in selected lines of mice with high or low antibody responses.
    Lagrange PH; Michel JC; Hurtrel B; Thickstun PM
    Ann Immunol (Paris); 1980; 131C(3):257-77. PubMed ID: 7406440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between cyclophosphamide-induced viral susceptibility and depletion of Junin virus-induced suppressor populations.
    Campetella OE; Galassi NV; Barrios HA
    J Med Virol; 1992 Jan; 36(1):32-8. PubMed ID: 1315368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
    Mayumi H; Good RA
    J Exp Med; 1989 Jan; 169(1):213-38. PubMed ID: 2642528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
    Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
    Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the immune system in the mouse. 1. Drug administration prior to antigen sensitization.
    Cottney J; Bruin J; Lewis AJ
    Agents Actions; 1980 Sep; 10(4):378-88. PubMed ID: 7446316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infiltration of liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide.
    Sava G; Giraldi T; Perissin L; Zorzet S; Mallardi F; Grill V
    Tumori; 1984 Dec; 70(6):477-83. PubMed ID: 6531789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, and L-phenylalanine mustard on B16, Cloudman S91, and Harding-Passey mouse melanomas.
    Hill HZ; Hill GJ; Miller CL; Pfaller M; Weiss K; Galin M
    Cancer Res; 1979 Mar; 39(3):934-9. PubMed ID: 427782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study on the immunosuppressive and lympholytic activity of optical isomers of cyclophosphamide.
    Tchórzewski H; Soszyńska W; Andrzejewski W; Pankiewicz K; Stec WJ
    Arch Immunol Ther Exp (Warsz); 1983; 31(3):329-33. PubMed ID: 6228204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on delayed-type hypersensitivity (DTH) reactions in the pleural cavity in mice: prolonged DTH reaction and its interruption by cyclophosphamide treatment.
    Higuchi Y; Yamamoto S
    Immunology; 1983 Jul; 49(3):529-36. PubMed ID: 6862525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential graft resistance of C3H mice pretreated with antitumor drugs against BALB/c bone marrow or lymphoma cells.
    Campanile F; Bonmassar E
    J Immunopharmacol; 1980; 2(4):527-42. PubMed ID: 7009759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein.
    Kawabata TT; White KL
    Cancer Res; 1988 Jan; 48(1):41-5. PubMed ID: 3257162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
    Testorelli C; Franco P; Goldin A; Nicolin A
    Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ; Falkson G
    Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.